Stock Events

Stock Events

Monte Rosa Therapeutics 

$10.76
33
-$0.11-1.01%Friday 20:00
+$0.09+0.84%Friday 23:14After hours

Statistics

Day High
10.77
Day Low
10.73
52W High
25.77
52W Low
9.68
Volume
57,109
Avg. Volume
-
Mkt Cap
917.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.45
-0.11
0.23
0.57
Expected EPS
-0.214527
Actual EPS
N/A

Financials

-31.23%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
123.67MRevenue
-38.63MNet Income

Analyst Ratings

$25.20Average Price Target
The highest estimate is ⁦28.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLUE. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
Microsoft
5
MSFT
Amazon
5
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including genetic disorders, which overlaps with Monte Rosa's focus on targeted therapies.
AMGEN
AMGN
Mkt Cap217.9B
Amgen is a biotechnology company that develops innovative human therapeutics, competing in the same biopharmaceutical market as Monte Rosa Therapeutics.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, similar to Monte Rosa's mission.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is a leading biotechnology company that invents, develops, and commercializes medicines for serious diseases, directly competing with Monte Rosa's therapeutic development.
Novartis
NVS
Mkt Cap268B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including areas where Monte Rosa is active.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, a market segment also targeted by Monte Rosa.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing in the broader biopharmaceutical space with a focus on genetic diseases, similar to Monte Rosa's approach.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, representing a direct competition in the innovative therapeutic space.

About

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Show More
CEO
Markus Warmuth
Employees
173
Country
United States
ISIN
US61225M1027

Listings

XNAS
US
GLUE
BOATS
BOATS
GLUE.BOATS

0 Comments

Share your thoughts

FAQs

What is Monte Rosa Therapeutics stock price today?▼
The current price of GLUE is $10.76 USD — it has decreased by -1.01% in the past 24 hours. Watch Monte Rosa Therapeutics stock price performance more closely on the chart.
What is Monte Rosa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Monte Rosa Therapeutics stocks are traded under the ticker GLUE.
Is Monte Rosa Therapeutics stock price growing?▼
GLUE stock has risen by +2.67% compared to the previous week, the month change is a +2.48% rise, over the last year Monte Rosa Therapeutics has showed a -16.26% decrease.
What is Monte Rosa Therapeutics market cap?▼
Today Monte Rosa Therapeutics has the market capitalization of 917.97M
When is the next Monte Rosa Therapeutics earnings date?▼
Monte Rosa Therapeutics is going to release the next earnings report on November 5, 2026.
What were Monte Rosa Therapeutics earnings last quarter?▼
GLUE earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.38 USD resulting in a -13.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Monte Rosa Therapeutics revenue for the last year?▼
Monte Rosa Therapeutics revenue for the last year amounts to 123.67M USD.
What is Monte Rosa Therapeutics net income for the last year?▼
GLUE net income for the last year is -38.63M USD.
How many employees does Monte Rosa Therapeutics have?▼
As of November 2, 2026, the company has 173 employees.
In which sector is Monte Rosa Therapeutics located?▼
Monte Rosa Therapeutics operates in the Health & Wellness sector.
When did Monte Rosa Therapeutics complete a stock split?▼
Monte Rosa Therapeutics has not had any recent stock splits.
Where is Monte Rosa Therapeutics headquartered?▼
Monte Rosa Therapeutics is headquartered in BOSTON, United States.